ASH 2020 | MRD assessment in R/R myeloma treated with VenKd
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the findings of an evaluation (NCT02899052) of measurable residual disease (MRD) in relapsed/refractory (R/R) multiple myeloma patients treated with venetoclax, carfilzomib and dexamethasone (VenKd) combined. MRD was assessed using next-generation sequencing (NGS) of bone marrow aspirates and FDG-PET/CT imaging. The overall response rate was 80%, including 41% achieving complete remission. The results were highly concordant in patients assessed by both methods. VenKd shows promising responses, particularly in t(11;14) and BCL-2high subgroups. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Luciano Costa, MD, PhD, has received research funding from Amgen and Janssen; and has received honoraria from Amgen, Janssen, BMS and Sanofi.
